Treatment of anemia in the diabetic patient with retinopathy and kidney disease

American Journal of Ophthalmology

Volumn 135, Issue 5, 2003, Pages 740-743

  Sinclair, Stephen H ^a   DelVecchio, Cherie ^b   Levin, Adeera ^c  

^a CROZER CHESTER MEDICAL CENTER   (United States)

^b PENNSYLVANIA COLLEGE OF OPTOMETRY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ENDOTHELIN; ERYTHROPOIETIN; HEMOGLOBIN; VASCULOTROPIN;

ANEMIA; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LASER COAGULATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0037404164     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)02149-9     Document Type: Editorial

References (37)

1. Bosman D., Winkler A., Marsden J., et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 24:2001;495-499.
2. Dikow R., Schwenger V., Schomig M., et al. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant. 17:(Suppl 1):2002;67-72.
3. Winkler A.S., Mardsen J., Chauduria K.R., Hambley H., Watkins P.J. Erythropoietin depletion and anaemia in diabetes mellitus. Diabetic Med. 16:1999;813-819.
4. Yun Y.S., Lee M.C., Yoo N.C., et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Practice. 46:1999;223-229.
5. Rarick M.U., Espina C.M., Colley D.T., et al. Treatment of a unique anemia in patients with IDDM with epoetin alfa. Diabetes Care. 21:1998;423-426.
6. Controneo P., Ricera B.M., Todaro L., et al. Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes Metab Res Rev. 16:2000;172-176.
7. Kojima J., Totsuka Y. Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Diabetes Res Clin Practice. 27:1995;229-233.
8. NKF-K/DOQI Guidelines for the evaluation, definition, and classification of chronic kidney disease Am J Kidney Dis 2001;37(Suppl):182-238.
9. Caro J., Erslev A. Erythropoietin assays and their use in the study of anemias. Contrib Nephrol. 66:1988;54-62.
10. Synthetic erythropoietin substitutes (I-50B-R2). Indications and limitations of coverage and/or medical necessity. Medicare Part B Newsletter No 02-027, Trailblazer Health Enterprizes, 2002;June 28:23-24.
11. Sinclair S Macular retinal capillary hemodynamics in diabetic patients. Ophthalmology. 98:1991;1580-1586.
12. Sinclair S., Mainster M. Diabetic macular edema new concepts of pathology and treatment [Editorial] . Seminars Ophthalmol. 14:1999;197-199.
13. Grunwald J., Riva C., Brucker A., et al. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch Ophthalmol. 104:1986;991-996.
14. Aiello L., Pierce E., Foley E., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 92:1995;10457-10461.
15. Quam T., Xu Q., Joussen A., et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 42:2001;2408-2413.
16. Qiao Q., Keinanen-Kiukaanniemi S., Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 50:1997;153-158.
17. Davis M., Fisher M., Gangnon R., et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss Early treatment diabetic retinopathy study report no. 18 . Invest Ophthalmol Vis Sci. 39:1998;233-252.
18. Shorb S. Anemia and diabetic retinopathy. Am J Ophthalmol. 100:1985;434-436.
19. Melberg N., Grand M., Rup D. The impact of acute lymphocytic leukemia on diabetic retinopathy. J Pediatr Hematol Oncol. 17:1995;81-84.
20. Friedman E., Brown C., Berman D. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis. 26:1995;202-208.
21. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction a clinical perspective . Endocrine Rev. 22:2001;36-52.
22. Benjamin L Glucose, VEGF-A and diabetic complications. Am J Pathol. 158:2001;1181-1184.
23. Grimm C., Wenzel A., Groszer M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nature Med. 8:2002;718-722.
24. Brines M., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 97:2000;10526-10531.
25. Cerami A., Brines M., Ghezzi P., Itri L.M. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant. 17:(Suppl 1):2002;8-12.
26. Zhu H., Jackson T., Bunn H.F. Detecting and responding to hypoxia. Nephrol Dial Transplant. 17:(Suppl 1):2002;3-7.
27. Duncan L., Heathcote J., Djurdjev O., Levin A. Screening for renal disease using serum creatinine who are we missing? Nephrol Dial Transplant. 16:2001;1042-1046.
28. Inomata S., Itoh M., Imai H., et al. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron. 75:1997;426-430.
29. Jungers P., Choukroun G., Oualim Z., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 16:2001;307-312.
30. Stevens L., Stigant C., Levin A. Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dialysis. 15:2002;8-13.
31. Rossert J.A., McClellan W.M., et al. Contribution of anemia to progression of renal disease a debate . Nephrol Dial Transplant. 17:(Suppl 1):2002;60-66.
32. Kuriyama S., Tomonari H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in the nondiabetic patient. Nephron. 77:1997;176-185.
33. Hayashi T., Suzuki A., Shoji T., et al. Cardiovascular effects of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 35:2000;250-256.
34. Silverberg D., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron a randomized controlled study . J Am Coll Cardiol. 37:2001;1775-1780.
35. Lopez Gomez J., Carrera F. What should the optimal target hemoglobin be? Kidney Intern. 61:(Suppl 80):2002;S39-S43.
36. Collins A. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Intern. 61:(Suppl 80):2002;S44-S48.
37. Muirhead N. A rationale for an individualized hemoglobin target. Nephrol Dial Transplant. 17:(Suppl 1):2002;2-7.